Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors.

Lu IL, Tsai KC, Chiang YK, Jiaang WT, Wu SH, Mahindroo N, Chien CH, Lee SJ, Chen X, Chao YS, Wu SY.

Eur J Med Chem. 2008 Aug;43(8):1603-11. doi: 10.1016/j.ejmech.2007.11.014. Epub 2007 Nov 29. Erratum in: Eur J Med Chem. 2009 Jun;44(6):2763.

PMID:
18207285
2.

Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.

Al-Masri IM, Mohammad MK, Taha MO.

ChemMedChem. 2008 Nov;3(11):1763-79. doi: 10.1002/cmdc.200800213.

PMID:
18989859
3.

Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.

Al-masri IM, Mohammad MK, Tahaa MO.

J Enzyme Inhib Med Chem. 2009 Oct;24(5):1061-6. doi: 10.1080/14756360802610761.

PMID:
19640223
4.

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Longenecker KL, Stewart KD, Madar DJ, Jakob CG, Fry EH, Wilk S, Lin CW, Ballaron SJ, Stashko MA, Lubben TH, Yong H, Pireh D, Pei Z, Basha F, Wiedeman PE, von Geldern TW, Trevillyan JM, Stoll VS.

Biochemistry. 2006 Jun 20;45(24):7474-82.

PMID:
16768443
5.

Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.

Wang L, Zhang B, Ji J, Li B, Yan J, Zhang W, Wu Y, Wang X.

Eur J Med Chem. 2009 Aug;44(8):3318-22. doi: 10.1016/j.ejmech.2009.03.021. Epub 2009 Mar 26.

PMID:
19375196
6.
7.
8.

Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.

Tsai TY, Hsu T, Chen CT, Cheng JH, Chiou MC, Huang CH, Tseng YJ, Yeh TK, Huang CY, Yeh KC, Huang YW, Wu SH, Wang MH, Chen X, Chao YS, Jiaang WT.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1908-12. doi: 10.1016/j.bmcl.2009.02.061. Epub 2009 Feb 21.

PMID:
19269819
9.

(3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Nitta A, Fujii H, Sakami S, Nishimura Y, Ohyama T, Satoh M, Nakaki J, Satoh S, Inada C, Kozono H, Kumagai H, Shimamura M, Fukazawa T, Kawai H.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5435-8. doi: 10.1016/j.bmcl.2008.09.042. Epub 2008 Sep 12.

PMID:
18819797
10.

Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2008 May;57(5):1331-9. doi: 10.2337/db07-1639. Epub 2008 Feb 25.

11.

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays.

Guasch L, Ojeda MJ, González-Abuín N, Sala E, Cereto-Massagué A, Mulero M, Valls C, Pinent M, Ardévol A, Garcia-Vallvé S, Pujadas G.

PLoS One. 2012;7(9):e44971. doi: 10.1371/journal.pone.0044971. Epub 2012 Sep 12.

12.

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Wu D, Jin F, Lu W, Zhu J, Li C, Wang W, Tang Y, Jiang H, Huang J, Liu G, Li J.

Chem Biol Drug Des. 2012 Jun;79(6):897-906. doi: 10.1111/j.1747-0285.2012.01365.x. Epub 2012 Mar 21.

PMID:
22381062
13.

Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.

Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni SS, Dutt C.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5021-5. doi: 10.1016/j.bmcl.2009.07.058. Epub 2009 Jul 12.

PMID:
19643608
14.

Selectivity among dipeptidyl peptidases of the S9b family.

Bjelke JR, Kanstrup AB, Rasmussen HB.

Cell Mol Biol (Noisy-le-grand). 2006 Dec 31;52(4):3-7.

PMID:
17543192
15.

Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.

Ahn JH, Park WS, Jun MA, Shin MS, Kang SK, Kim KY, Rhee SD, Bae MA, Kim KR, Kim SG, Kim SY, Sohn SK, Kang NS, Lee JO, Lee DH, Cheon HG, Kim SS.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6525-9. doi: 10.1016/j.bmcl.2008.10.076. Epub 2008 Oct 21.

PMID:
18996694
16.

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

Kirby M, Yu DM, O'Connor S, Gorrell MD.

Clin Sci (Lond). 2009 Sep 28;118(1):31-41. doi: 10.1042/CS20090047. Review.

PMID:
19780719
17.

New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study.

Almasri IM, Taha MO, Mohammad MK.

Arch Pharm Res. 2013 Nov;36(11):1326-37. doi: 10.1007/s12272-013-0224-1. Epub 2013 Aug 6.

PMID:
23918649
18.

Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.

Park WS, Kang SK, Jun MA, Shin MS, Kim KY, Rhee SD, Bae MA, Kim MS, Kim KR, Kang NS, Yoo SE, Lee JO, Song DH, Silinski P, Schneider SE, Ahn JH, Kim SS.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1366-70. doi: 10.1016/j.bmcl.2011.01.041. Epub 2011 Jan 14.

PMID:
21306895
19.

Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors.

Zhu Y, Xia S, Zhu M, Yi W, Cheng J, Song G, Li Z, Lu P.

Eur J Med Chem. 2010 Nov;45(11):4953-62. doi: 10.1016/j.ejmech.2010.08.002. Epub 2010 Aug 12.

PMID:
20800322
20.

Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.

Fukushima H, Hiratate A, Takahashi M, Saito-Hori M, Munetomo E, Kitano K, Saito H, Takaoka Y, Yamamoto K.

Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1110-7.

Supplemental Content

Support Center